Merck has confirmed that it is terminating a Phase II/III trial evaluating V710, a vaccine against Staphylococcus aureus, licensed from Intercell.
Merck has confirmed that it is terminating a Phase II/III trial evaluating V710, a vaccine against Staphylococcus aureus, licensed from Intercell.
The news has sent Intercell's share price diving a further 22% in today's trading to €4.03 (2pm; 8 June), having...
Create an account to read this article
Already a subscriber?
With no advances for decades, the STI could soon be facing two new antibiotic threats, while a third novel therapy has just entered the clinic.
The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.
After an Aug. 6 safety labeling change, the FDA became aware of “more compelling evidence” that the risk for serious chikungunya-like illness is not limited to older adults, CBER Director Prasad said.
The drugmaker announced the launch of an at-home version of its nasal FluMist vaccine, as more companies are looking into direct-to-patient drug sales in response to Trump’s most favored nation pricing proposals.
The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.
Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.
The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.
